StockData
Novo Nordisk A S logo

Novo Nordisk A S

NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$37.82−1.05 (-2.70%)

Close on Nov 20, 2026Market cap $168.87BP/E 11.1Yield –

Novo Nordisk A S Parent Company by Year

Parent Company — Contract manufacturer (CMO) purchase obligations (DKKm)

Novo Nordisk A S Parent Company: 91,031.00 DKKm in FY2025, up 28.1% from a year earlier.

Latest, FY2025
91,031.00
Period ended Dec 31, 2025
Change on a year earlier
+28.1%
71,061.00 in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below

Where the FY2025 figure comes from

“|| Purchase obligation relating to contract manufacturers | 91,031 | 71,061”

Source: Form 20-F (filed 2026-02-04) ↗

Reported in Novo Nordisk Annual Report — Financial Statements of the Parent Company (Note 15).

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedParent Company — Contract manufacturer (CMO) purchase obligations (DKKm)Year on yearSource
FY2025Dec 31, 202591,031.00+28.1%Form 20-F (filed 2026-02-04) ↗
FY2024Dec 31, 202471,061.00+114.6%Form 20-F (filed 2026-02-04) ↗
FY2023Dec 31, 202333,107.00–Form 20-F (filed 2025-02-05) ↗

Breakdown

What makes up parent Company

Cite this data

StockData. (2026). Novo Nordisk A S Parent Company, annual FY2023–FY2025 [Data set]. Compiled from Novo Nordisk A S SEC filings and investor materials. https://stockdatahq.com/stocks/nvo/kpis/parent-comm-cmo

See every metric in the Novo Nordisk A S KPI table. Data updated Nov 3, 2026.

See a number that looks wrong?